References
ADVERSE EVENTS, ADVERSE EVENT
HBsAg (Summary of subject disposition in Phase I study.Percentage change in HBsAg in Phase I study. (Mean HBsAg and HBsAg clearance rate at the end of the animal study.Summary of demographics and baseline characteristics in the Phase I clinical study.Max: maximal; Min: minimal; SD: standard deviation.Summary of adverse events (AEs) in the Phase I study.AE: adverse event; SAE: serious adverse event; ALT: alanine transaminase; AST: aspartate aminotransferase. Note: (1) % = percentage of patients with n as the denominator.